Aditya Sunkaria
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aditya Sunkaria has a total of 73 co-authors. Here are the top co-authors by number of shared publications:
- Willayat Yousuf Wani
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
9 shared publications Kiran Dip Gill
8 shared publicationsDeep Raj Sharma
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
7 shared publications- Ramesh Kandimalla
Department of Biochemistry, Government Medical College, Narsampet, Warangal, Telangana, India
7 shared publications Amanjit Bal
6 shared publications- Kiran Dip Gill
Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India
5 shared publications
Latest Publications
- 7 May 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 119, 103168
The mitochondria-synapse axis in Alzheimer’s disease: Lost coordination in early stages
- 7 May 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 119, 103168
The mitochondria-synapse axis in Alzheimer’s disease: Lost coordination in early stages
- 3 December 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 246
Orexin-A and Circadian Disruption in Alzheimer’s Disease: Implications for Amyloid-Beta Pathology
Alzheimer's disease (AD) is characterized by cognitive decline, circadian rhythm disruptions, and accumulation of Aβ plaques. Orexin-A, a neuropeptide involved in regulating sleep and circadian rhythms, has been implicated in these processes, although its specific role in modulating β-amyloid (Aβ) aggregation remains unclear. This study investigates how orexin-A influences Aβ aggregation and its impact on cognitive and circadian dysfunctions in AD mice subjected to acute sleep deprivation (ASD). Behavioural assessments showed significant cognitive deficits following ASD, including impaired recognition and spatial memory. Proteomic analysis revealed 1380 modulated proteins, including 105 associated with AD, 56 with cognitive functions, 11 with circadian rhythm, and six involved in Aβ clearance. Further analysis showed dysregulation of Clock and Bmal1 levels, along with reduced orexin-A expression after ASD. Since orexin-A regulates both sleep and circadian rhythm, investigating its role in modulating Aβ aggregation is essential for understanding the pathophysiology of AD. To explore this, we performed molecular dynamics (MD) simulations to gain insights into the molecular interactions between orexin-A and Aβ. Analysis revealed that orexin-A binds Aβ with high affinity and effectively inhibits its aggregation, suggesting a potential mechanism for reducing Aβ-induced neurotoxicity. These results suggest that orexin-A may play an important role in modulating Aβ aggregation and circadian dysfunction in AD, as supported by simulation results. Further studies manipulating orexin-A levels are needed to confirm its role in this context. Our findings highlight orexin-A as a potential therapeutic target for slowing cognitive decline and neurodegeneration in AD by restoring circadian and sleep-wake regulation.
- 3 December 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 63 (1) , 246
Orexin-A and Circadian Disruption in Alzheimer’s Disease: Implications for Amyloid-Beta Pathology
Alzheimer's disease (AD) is characterized by cognitive decline, circadian rhythm disruptions, and accumulation of Aβ plaques. Orexin-A, a neuropeptide involved in regulating sleep and circadian rhythms, has been implicated in these processes, although its specific role in modulating β-amyloid (Aβ) aggregation remains unclear. This study investigates how orexin-A influences Aβ aggregation and its impact on cognitive and circadian dysfunctions in AD mice subjected to acute sleep deprivation (ASD). Behavioural assessments showed significant cognitive deficits following ASD, including impaired recognition and spatial memory. Proteomic analysis revealed 1380 modulated proteins, including 105 associated with AD, 56 with cognitive functions, 11 with circadian rhythm, and six involved in Aβ clearance. Further analysis showed dysregulation of Clock and Bmal1 levels, along with reduced orexin-A expression after ASD. Since orexin-A regulates both sleep and circadian rhythm, investigating its role in modulating Aβ aggregation is essential for understanding the pathophysiology of AD. To explore this, we performed molecular dynamics (MD) simulations to gain insights into the molecular interactions between orexin-A and Aβ. Analysis revealed that orexin-A binds Aβ with high affinity and effectively inhibits its aggregation, suggesting a potential mechanism for reducing Aβ-induced neurotoxicity. These results suggest that orexin-A may play an important role in modulating Aβ aggregation and circadian dysfunction in AD, as supported by simulation results. Further studies manipulating orexin-A levels are needed to confirm its role in this context. Our findings highlight orexin-A as a potential therapeutic target for slowing cognitive decline and neurodegeneration in AD by restoring circadian and sleep-wake regulation.
- 5 November 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (22) , 4351-4363
Machine Learning–Based Bioactivity Prediction and Descriptor-Guided Rational Design of Amyloid-β Aggregation Inhibitors
Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which amyloid-β (Aβ) aggregation plays a pivotal role in its onset and progression. Inhibiting Aβ aggregation is a promising therapeutic strategy; however, its intrinsically disordered and conformationally flexible nature hinders both conventional and computational inhibitor design. Moreover, experimental development of Aβ inhibitors, encompassing molecular design, synthesis, and biological evaluation through repeated assays, is a slow, labor-intensive, and resource-intensive process. Therefore, robust design guidelines and predictive tools are essential for accelerating the discovery of Aβ inhibitors. To overcome these limitations, we developed a machine-learning-based, user-friendly web platform, Amylo-IC50Pred (https://amyloic50pred.vercel.app/), for rapid virtual screening of small molecules targeting Aβ aggregation. The platform integrates two classification models and one regression model, trained on 584 biologically validated compounds. For inhibitor-decoy discrimination, the Random Forest algorithm achieved perfect accuracy (100%). Potency classification into potent, moderately potent, and poor inhibitors was best achieved using Histogram-based Gradient Boosting (81% accuracy). The IC50 regression model, also based on Random Forest, achieved a coefficient of determination (R2) of 0.93, demonstrating strong predictive performance. 2D and 3D key molecular properties such as hydrophobicity, shape and charge distribution, and molecular symmetry were identified as critical contributors to model performance. Importantly, these identified properties provide valuable insights into the molecular features that govern Aβ aggregation inhibition and can serve as a foundation for rational design of potent and selective Aβ aggregation inhibitors. Amylo-IC50Pred thus represents a valuable resource for accelerating AD drug discovery.
- 5 November 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (22) , 4351-4363
Machine Learning–Based Bioactivity Prediction and Descriptor-Guided Rational Design of Amyloid-β Aggregation Inhibitors
Alzheimer's disease (AD) is a progressive neurodegenerative disorder in which amyloid-β (Aβ) aggregation plays a pivotal role in its onset and progression. Inhibiting Aβ aggregation is a promising therapeutic strategy; however, its intrinsically disordered and conformationally flexible nature hinders both conventional and computational inhibitor design. Moreover, experimental development of Aβ inhibitors, encompassing molecular design, synthesis, and biological evaluation through repeated assays, is a slow, labor-intensive, and resource-intensive process. Therefore, robust design guidelines and predictive tools are essential for accelerating the discovery of Aβ inhibitors. To overcome these limitations, we developed a machine-learning-based, user-friendly web platform, Amylo-IC50Pred (https://amyloic50pred.vercel.app/), for rapid virtual screening of small molecules targeting Aβ aggregation. The platform integrates two classification models and one regression model, trained on 584 biologically validated compounds. For inhibitor-decoy discrimination, the Random Forest algorithm achieved perfect accuracy (100%). Potency classification into potent, moderately potent, and poor inhibitors was best achieved using Histogram-based Gradient Boosting (81% accuracy). The IC50 regression model, also based on Random Forest, achieved a coefficient of determination (R2) of 0.93, demonstrating strong predictive performance. 2D and 3D key molecular properties such as hydrophobicity, shape and charge distribution, and molecular symmetry were identified as critical contributors to model performance. Importantly, these identified properties provide valuable insights into the molecular features that govern Aβ aggregation inhibition and can serve as a foundation for rational design of potent and selective Aβ aggregation inhibitors. Amylo-IC50Pred thus represents a valuable resource for accelerating AD drug discovery.
- 25 February 2025
- Published by Elsevier in Behavioural Brain Research
- Vol. 484, 115505
Unlocking the therapeutic promise of miRNAs in promoting amyloid-β clearance for Alzheimer's disease
- 25 February 2025
- Published by Elsevier in Behavioural Brain Research
- Vol. 484, 115505
Unlocking the therapeutic promise of miRNAs in promoting amyloid-β clearance for Alzheimer's disease
- 10 January 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (3) , 500-512
From Plant to Pathway: Molecular Mechanisms of Ruscogenin in Preventing Amyloid-Beta Aggregation through Computational and Experimental Approaches
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, extracellular amyloid-β (Aβ) plaque accumulation, and intracellular neurofibrillary tangles. Recent efforts to find effective therapies have increased interest in natural compounds with multifaceted effects on AD pathology. This study explores natural compounds for their potential to mitigate AD pathology using molecular docking, ADME screening, and in vitro assays, with ruscogenin─a steroidal sapogenin from Ruscus aculeatus─emerging as a promising candidate. Ruscogenin, known for its antioxidant and anti-inflammatory properties, was investigated for its effects on Aβ aggregation, a critical process in AD progression. In vitro assays demonstrated that ruscogenin inhibits Aβ oligomerization at equimolar and higher molar ratios. Molecular dynamics (MD) simulations further revealed that ruscogenin targets aggregation-prone regions, reducing noncovalent interactions and the solvent-accessible surface area of Aβ aggregates. These effects were concentration-dependent, with higher concentrations yielding optimal inhibition, pointing to a multiphasic behavior in ruscogenin's modulation of Aβ aggregation. This study highlights ruscogenin's potential as a natural therapeutic agent for AD, capable of addressing both oxidative stress and inflammation. The findings lay the groundwork for further exploration of ruscogenin-based interventions and underscore the broader potential of natural compounds in AD treatment strategies.
- 10 January 2025
- Published by American Chemical Society (ACS) in ACS Chemical Neuroscience
- Vol. 16 (3) , 500-512
From Plant to Pathway: Molecular Mechanisms of Ruscogenin in Preventing Amyloid-Beta Aggregation through Computational and Experimental Approaches
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, extracellular amyloid-β (Aβ) plaque accumulation, and intracellular neurofibrillary tangles. Recent efforts to find effective therapies have increased interest in natural compounds with multifaceted effects on AD pathology. This study explores natural compounds for their potential to mitigate AD pathology using molecular docking, ADME screening, and in vitro assays, with ruscogenin─a steroidal sapogenin from Ruscus aculeatus─emerging as a promising candidate. Ruscogenin, known for its antioxidant and anti-inflammatory properties, was investigated for its effects on Aβ aggregation, a critical process in AD progression. In vitro assays demonstrated that ruscogenin inhibits Aβ oligomerization at equimolar and higher molar ratios. Molecular dynamics (MD) simulations further revealed that ruscogenin targets aggregation-prone regions, reducing noncovalent interactions and the solvent-accessible surface area of Aβ aggregates. These effects were concentration-dependent, with higher concentrations yielding optimal inhibition, pointing to a multiphasic behavior in ruscogenin's modulation of Aβ aggregation. This study highlights ruscogenin's potential as a natural therapeutic agent for AD, capable of addressing both oxidative stress and inflammation. The findings lay the groundwork for further exploration of ruscogenin-based interventions and underscore the broader potential of natural compounds in AD treatment strategies.
- 1 October 2024
- Published by Elsevier in Neuroscience
- Vol. 560, 254-262
Proteomic insights into early-stage Alzheimer’s disease: Identifying key neuronal proteins impacted by amyloid beta oligomers in an in vitro model
- 1 October 2024
- Published by Elsevier in Neuroscience
- Vol. 560, 254-262
Proteomic insights into early-stage Alzheimer’s disease: Identifying key neuronal proteins impacted by amyloid beta oligomers in an in vitro model
- 7 July 2023
- Published by Elsevier in Ageing Research Reviews
- Vol. 90, 102002
The hidden players: Shedding light on the significance of post-translational modifications and miRNAs in Alzheimer's disease development
- 7 July 2023
- Published by Elsevier in Ageing Research Reviews
- Vol. 90, 102002
The hidden players: Shedding light on the significance of post-translational modifications and miRNAs in Alzheimer's disease development
- 29 June 2022
- Published by Springer Nature in Biogerontology
- Vol. 23 (6) , 809-824
Dietary intervention with Tinospora cordifolia improved aging-related decline in locomotor coordination and cerebellar cell survival and plasticity in female rats
Reduced bone mineral density, and muscle strength are the hallmark of aging-related motor coordination deficits and related neuropathologies. Since cerebellum regulates motor movements and balance perception of our body, therefore it may be an important target to control the age-related progression of motor dysfunctions. Dry stem powder of Tinospora cordifolia (TCP) was tested as a food supplement to elucidate its activity to attenuate age-associated locomotor dysfunctions. Intact acyclic middle-aged female rats were used in this study as the model system of the transition phase from premenopause to menopause in women along with cycling young adult rats. Normal chow or 30% High Fat Diet (HFD), supplemented with or without TCP was fed to animals for 12 weeks and then tested for locomotor performance on rotarod followed by post-sacrifice protein expression studies. In comparison to young adults, middle-aged animals showed an increase in number of falls and lesser time spent in rotarod performance test, whereas, animals given TCP supplemented feed showed improvement in performance with more pronounced effects observed in normal chow than HFD fed middle-aged rats. Further, due to its multicomponent nature TCP was found to target the expression of various markers of neuroinflammation, apoptosis, cell survival, and synaptic plasticity in the cerebellum region. The current findings suggest that TCP supplementation in the diet may prove to be a potential interventional strategy for the management of frailty and fall-associated morbidities caused by aging-related deterioration of bone mineral density, and muscle strength. Graphical abstract
- 29 June 2022
- Published by Springer Nature in Biogerontology
- Vol. 23 (6) , 809-824
Dietary intervention with Tinospora cordifolia improved aging-related decline in locomotor coordination and cerebellar cell survival and plasticity in female rats
Reduced bone mineral density, and muscle strength are the hallmark of aging-related motor coordination deficits and related neuropathologies. Since cerebellum regulates motor movements and balance perception of our body, therefore it may be an important target to control the age-related progression of motor dysfunctions. Dry stem powder of Tinospora cordifolia (TCP) was tested as a food supplement to elucidate its activity to attenuate age-associated locomotor dysfunctions. Intact acyclic middle-aged female rats were used in this study as the model system of the transition phase from premenopause to menopause in women along with cycling young adult rats. Normal chow or 30% High Fat Diet (HFD), supplemented with or without TCP was fed to animals for 12 weeks and then tested for locomotor performance on rotarod followed by post-sacrifice protein expression studies. In comparison to young adults, middle-aged animals showed an increase in number of falls and lesser time spent in rotarod performance test, whereas, animals given TCP supplemented feed showed improvement in performance with more pronounced effects observed in normal chow than HFD fed middle-aged rats. Further, due to its multicomponent nature TCP was found to target the expression of various markers of neuroinflammation, apoptosis, cell survival, and synaptic plasticity in the cerebellum region. The current findings suggest that TCP supplementation in the diet may prove to be a potential interventional strategy for the management of frailty and fall-associated morbidities caused by aging-related deterioration of bone mineral density, and muscle strength. Graphical abstract
- 18 March 2022
- Published by Springer Nature in Neurochemical Research
- Vol. 47 (7) , 1799-1815
Sleep Disturbance and Alzheimer’s Disease: The Glial Connection
Poor quality and quantity of sleep are very common in elderly people throughout the world. Growing evidence has suggested that sleep disturbances could accelerate the process of neurodegeneration. Recent reports have shown a positive correlation between sleep deprivation and amyloid-β (Aβ)/tau aggregation in the brain of Alzheimer’s patients. Glial cells have long been implicated in the progression of Alzheimer’s disease (AD) and recent findings have also suggested their role in regulating sleep homeostasis. However, how glial cells control the sleep–wake balance and exactly how disturbed sleep may act as a trigger for Alzheimer’s or other neurological disorders have recently gotten attention. In an attempt to connect the dots, the present review has highlighted the role of glia-derived sleep regulatory molecules in AD pathogenesis. Graphical Abstract Role of glia in sleep disturbance and Alzheimer’s progression.
- 18 March 2022
- Published by Springer Nature in Neurochemical Research
- Vol. 47 (7) , 1799-1815
Sleep Disturbance and Alzheimer’s Disease: The Glial Connection
Poor quality and quantity of sleep are very common in elderly people throughout the world. Growing evidence has suggested that sleep disturbances could accelerate the process of neurodegeneration. Recent reports have shown a positive correlation between sleep deprivation and amyloid-β (Aβ)/tau aggregation in the brain of Alzheimer’s patients. Glial cells have long been implicated in the progression of Alzheimer’s disease (AD) and recent findings have also suggested their role in regulating sleep homeostasis. However, how glial cells control the sleep–wake balance and exactly how disturbed sleep may act as a trigger for Alzheimer’s or other neurological disorders have recently gotten attention. In an attempt to connect the dots, the present review has highlighted the role of glia-derived sleep regulatory molecules in AD pathogenesis. Graphical Abstract Role of glia in sleep disturbance and Alzheimer’s progression.
- 1 March 2020
- Published by Elsevier in Neuroscience
- Vol. 429, 225-234
Sulforaphane Attenuates Aβ Oligomers Mediated Decrease in Phagocytic Activity of Microglial Cells
- 1 March 2020
- Published by Elsevier in Neuroscience
- Vol. 429, 225-234
Sulforaphane Attenuates Aβ Oligomers Mediated Decrease in Phagocytic Activity of Microglial Cells